Introduction
The incidence of twin pregnancies has steadily increased for several years worldwide. 1, 2 In this population, the rate of preterm delivery reached 41% before 37 weeks of gestation and 7% before 32 weeks of gestation, 3 inducing subsequent neonatal complications and long-term impact on morbidity. [3] [4] [5] Several randomised trials, [6] [7] [8] [9] and a meta-analysis, 10 have consistently found that the administration of antenatal corticosteroid (ACS) to women at risk for preterm delivery effectively reduces neonatal mortality and morbidity, such as respiratory distress syndrome, intraventricular haemorrhage, and necrotising enterocolitis in singletons. The ACS therapy protocol recommended for all fetuses at risk for preterm delivery between 24 +0 and 33 +6 weeks of gestation consists of two doses of 12 mg of intramuscular betamethasone 24 hours apart or four doses of 6 mg of intramuscular dexamethasone 12 hours apart. 11 An additional course of ACS should be carefully considered after 7 days for women who remain at risk of preterm birth before 34 weeks of gestation. 12 The same ACS protocol is recommended for twin pregnancies at risk for preterm delivery, despite scarce data and controversial results reported in the literature. 4, [13] [14] [15] [16] The Cochrane Review published by Roberts and Dalziel in 2006 concluded that further research is needed to support the use of ACS in multiple pregnancies. 17 The pharmacokinetics of corticosteroids appear to be accelerated in twin pregnancies, 18 suggesting that higher ACS doses may be needed in twins than in singletons.
The administration-to-delivery interval is a significant consideration. Some studies have suggested that ACS is less effective when the administration-to-delivery interval exceeds 7 days, 17, [19] [20] [21] [22] and this may influence the decision to repeat doses. The conclusion that ACS is less effective if administered more than 7 days before delivery remains uncertain, however, even in singletons. [23] [24] [25] In twins, the main studies investigated the efficacy for respiratory complications only. 26, 27 A likely reduction of ACS efficacy after a long administration-to-delivery interval particularly justifies exploring the risk-benefit ratio of repeated courses in twin pregnancies.
This study aimed to assess the impact of ACS therapy on short-term neonatal outcomes in preterm twins born before 32 weeks of gestation. For this purpose, we explored the effect of a single complete course of ACS according to administration-to-delivery interval (≤7 versus >7 days), and the impact of repeated courses (an additional injection or a second complete course) versus one single complete course of ACS.
Methods

Design and population
EPIPAGE-2 is a nationwide observational multicentre prospective cohort study of neonates born between 22 and 34 completed weeks of gestation in France in 2011. The study was designed to document the causes of premature births and to report on health outcomes in children up to the age of 12 years, and on early predictors of outcomes, including medications and respiratory support. The detailed protocol has been published elsewhere. 28 The study was approved by the Committee for the Protection of Persons Participating in Biomedical Research. Consent to participate was obtained from all parents, as appropriate.
In the present study, all twin neonates born between 24 and 31 completed weeks of gestation and alive on admission to neonatal intensive care units (NICUs) were eligible for inclusion. Only one twin was included if the co-twin died during delivery or in the delivery room. We excluded infants who died during delivery or in the delivery room because their death is often the result of fetal distress unrelated to corticosteroid administration or effect. Their recruitment period varied according to gestational age (GA): 8 months for infants born at 24-26 weeks of gestation and 6 months for those born at 27-31 weeks of gestation. High-order multiple gestation pregnancies (triplets or more), pregnancies complicated by twin-twin transfusion syndromes (TTTSs), or co-twin fetal death and infants with major congenital anomalies were excluded.
Data collection
At birth, and during the neonatal period, data were collected from medical charts by health professionals. They recorded demographics, pregnancy complications and management, child's condition at birth, neonatal diseases, care, and medications. Maternal data comprised age, country of birth, prepregnancy body mass index (BMI), parity (number of previous live births: nulliparous, 1, or ≥2), history of premature delivery (yes/no), pregnancy monitoring (regular or not), infertility treatment (yes/no), smoking status during pregnancy (smoker/non-smoker), gestational diabetes (yes/no), hypertensive disease (yes/no), tocolytic treatment (yes/no), preterm labour (yes/no), chorioamnionitis (yes/no), administration of magnesium sulphate for neuroprotection (yes/ no), premature rupture of membranes (PROM) at least 12 hours before the onset of labour (yes/no), and type of labour (induced versus spontaneous). Regular pregnancy monitoring was defined as at least one medical consultation or one ultrasound examination before 15 weeks of gestation, and regular consultations or hospitalisation during pregnancy. Gestational age at delivery was estimated based on the last menstrual period or an ultrasound examination performed during the first trimester. Perinatal data included fetal sex, oligohydramnios (yes/no), mode of delivery (vaginal versus caesarean), birthweight, and Apgar score ≤7 at 5 minutes (yes/no). Infants with birthweights below the tenth percentile for each week of GA of the French AUDI-POG curves were considered small for gestational age. 29 
ACS therapy
A single complete course of ACS therapy was defined as two doses of 12 mg betamethasone, according to recommendations. Exposure to antenatal corticosteroids was categorised into four groups: one single complete course with ACS-to-delivery interval ≤7 days (single course ≤7 days), one single complete course with ACS-to-delivery >7 days (single course >7 days) (both were entered in the 'single complete course' group), additional injection or second complete course ('repeated courses'), and no administration. An additional ACS injection was defined as one ACS dose more than 7 days after the first complete single course without completing the second course, whereas a second complete course was defined as one-second complete ACS course. As we wished to examine the effectiveness of ACS at the recommended dose, pregnancies with missing data on ACS courses (42 eligible infants) and those who had received incomplete first courses (140 eligible infants) were excluded from the analysis.
Outcomes
The following short-term neonatal outcomes were considered: severe bronchopulmonary dysplasia [BPD, defined as mechanical ventilator support, continuous positive airway pressure (CPAP), or ≥30% supplementary oxygen at 36 weeks of gestation, and supplementary oxygen for at least 28 days], neurological complications [cystic periventricular leukomalacia (PVL) or intraventricular haemorrhage (IVH) grade III/IV], and in-hospital mortality. PVL and IVH were determined by cranial ultrasonography. Survivors at hospital discharge who had no cranial ultrasound assessment (2.2% of the neonates included) were considered free from severe cerebral lesions. A composite indicator, defined as at least one of the three following outcomes -in-hospital mortality, bilateral PVL, or IVH grade III/IV -was considered to reflect a severe outcome.
Statistical analysis
Observations were weighted according to the sampling strategy. Maternal and pregnancy characteristics were compared between the groups (single complete course, repeated courses, or no course) with Wilcoxon or v 2 tests, as appropriate. We first performed bivariate analyses then multivariable logistic regression models to relate ACS therapy (single complete course according to an administration-to-delivery interval versus none, and repeated courses versus single complete course) to each neonatal outcome in turn. Potential confounding factors, associated at 20% level with both neonatal outcomes and ACS exposure in bivariate analysis, were taken into consideration. We also included GA and small for gestational age in all multivariable models.
Adjusted odds ratios (aORs) and their 95% confidence intervals (95% CIs) were estimated from the initial multivariable model. Analyses were stratified by GA: 24-27 weeks of gestation and 28-31 weeks of gestation only for bivariate analyses.
From analyses based on the infant as the statistical unit, we estimated clustered robust standard errors that took into account the clustering of children within mothers with twin pregnancies. 30 P values of <0.05 were considered statistically significant. Analyses were performed using STATA 11.2.
Results
Between 28 March and 31 December 2011, 3667 neonates born between 24 and 31 completed weeks of gestation and alive at admission to NICUs were recruited into the EPIPAGE-2 study, including 1183 infants delivered from multiple pregnancies (in addition, there were 30 infants who died in the delivery room and 113 were stillborn or their mothers had undergone medical termination of pregnancy). Of these 1183 infants, 251 were not included because they were triplets or more (n = 87), presented with TTTS (n = 99), their co-twin had died in utero (n = 44), or they had major congenital anomalies (n = 21). After exclusion of mothers with incomplete courses or missing ACS data, the final sample consisted of 750 twin neonates (Figure 1) .
Maternal, pregnancy, and neonatal characteristics are summarised in Table S1 . Of the 390 mothers of twins, 261 (66.5%, weighted percentage) received a single complete ACS course, 67 (18.0%) received repeated courses (26 with an additional injection and 41 with a second course), and 62 (15.5%) received no ACS. Of those who had a single complete course, 142 had an interval between the first ACS administration and delivery of ≤7 days and 119 had an interval of >7 days (overall median interval 6 days; interquartile range, IQR 3-15 days). Regular monitoring of pregnancy (95.5 versus 88.4%, P = 0.038) and tocolytic treatment (75.6 versus 41.7%, P < 0.001) were significantly more frequent in the single ACS course group compared with the no ACS group. The repeated ACS courses group differed from the single course group by less frequent premature rupture of membranes (23.7 versus 45.2%, P = 0.002) and chorioamnionitis (13.7 versus 28.8%, P = 0.013). Table S2 presents short-term outcomes according to GA groups and ACS status. The proportion of twin neonates receiving a single course ≤7 days decreased between 24-27 weeks of gestation and 28-31 weeks of gestation, whereas the proportion of twin neonates receiving more than one single complete course increased. In twins born at 24-31 weeks of gestation, the frequencies of PVL or IVH grade III/IV, in-hospital mortality, and severe composite outcome were significantly lower with a single complete ACS course, whichever time-to-delivery interval was considered, compared with no ACS. Neonates who received an additional injection or second complete course had a lower incidence of in-hospital mortality (0.8%, 95% CI 0.1-5.3%, versus 15.5%, 95% CI 9.7-23.8%, P = 0.012) than the single course group. In twins born at 24-27 weeks of gestation, neonates who received a single complete ACS course had a significantly lower rate of PVL or IVH grade III/IV, and of severe composite outcome, than the no ACS group, whereas BPD and in-hospital mortality frequencies did not significantly differ between single course (≤7 days or >7 days) and no ACS groups. Regarding the group born at 28-31 weeks of gestation, the occurrence of the composite outcome was lower after a single ACS course ≤7 days than in the no ACS group (0.6%, 95% CI 0.1-4.2, versus 6.3%, 95% CI 2.4-15.1, P = 0.023).
After adjustment for GA and other relevant confounding factors (Table S3) , we observed that a single complete course with an ACS-to-delivery interval of ≤7 days was associated with a significantly reduced rate of all neonatal outcomes analysed, except severe BPD, compared with the no ACS group: IVH grade III/IV or PVL (aOR 0.20, 95% CI 0.08-0.48), in-hospital mortality (aOR 0.27, 95% CI 0.12-0.62), and composite outcome (aOR 0.13, 95% CI 0.06-0.29). One single course with an ACS-to-delivery interval of >7 days was associated only with a reduced rate of IVH grade III/IV or PVL (aOR 0.30, 95% CI 0.12-0.74) and severe composite indicator (aOR 0.27, 95% CI 0.12-0.64). The incidence of severe BPD was not significantly lower after a single complete ACS course than after no ACS administration, regardless of the administration-todelivery interval. Frequencies of all neonatal outcomes analysed did not significantly differ between the repeated course and the single complete ACS course groups after adjustment.
Discussion
Main findings
We found that a single complete ACS course significantly reduced the occurrence of neurological complications and composite outcome in preterm twins born between 24 and 31 completed weeks of gestation, as previously demonstrated in singletons. Regarding in-hospital mortality, only a single ACS course with an ACS-to-delivery interval of ≤7 days significantly improved this outcome, compared with no ACS; however, a single course of ACS did not significantly reduce the incidence of severe BPD compared with no treatment in the GA group considered. 
Strengths and limitations
These results are based on a population-based nationwide cohort study that included all premature babies born during a given period throughout France (excepting a single administrative region). The parental participation rate was high (93%), resulting in a large sample of 750 twin infants from 390 mothers. This observational design is the only ethically acceptable design to explore our hypothesis, given the current recommendations on ACS administration in women at risk for preterm delivery, including multiple pregnancies. We observed various practices in the administration of ACS therapy, with numerous incomplete courses or repeated courses (28.9% of our target population), possibly related to specific centres or to emergencies. Despite prospective data collection, information on ACS therapy was sometimes missing (42 cases, 4.5%), resulting in exclusions from analysis and lower statistical power. Cases excluded from analysis (missing or incomplete ACS courses) differed slightly from those included, with less frequent premature rupture of membranes, chorioamniotis, or Apgar score ≤7 at 5 minutes, and more frequent spontaneous labour (data not shown). Our analyses were adjusted for all relevant factors that showed an imbalance between groups; however, mothers who received no ACS may correspond to situations with poor prognosis, with some confounding biases ignored in our analysis. The non-significant effect on severe BPD incidence might result from a lack of power, given our low rates of severe BPD. Our study included twins born between 24 +0 and 24 +6 weeks of gestation, and alive at admission to NCIUs (18 twins in our final sample), whereas in this GA category the decision to administer ACS depends on the management policies of the centre. Nevertheless, the US National Institutes of Health (NIH) Consensus Development Panel and the Royal College of Obstetricians and Gynaecologists (RCOG) recommend that all fetuses between 24-34 weeks of gestation at risk for preterm delivery should be considered candidates for ACS therapy. 11, 31 Although the centre is an essential element in characterising pregnancy management, we did not take this into consideration for adjustment in statistical models because of the difficulty in defining a centre for each pregnancy (antepartum hospitalisation, health facility that delivered ACS therapy, or health facility that carried out the delivery). Although chorionicity is a known factor of perinatal mortality in twin pregnancies, 32 we could not adjust for it because of missing data.
Interpretation
Some studies demonstrated significantly reduced neonatal adverse outcomes after ACS therapy in twins, but this reduction was often more limited than that observed in singletons. Al-Yatama et al. 4 found significantly reduced respiratory distress syndrome (RDS) only for repeated prophylactic doses, compared with no ACS, and Ardila et al. 15 only found a reduction in infants born at 28-32 weeks of gestation or in moderate and severe outcomes. Conversely, other studies observed no reduction of neonatal adverse outcomes after ACS therapy in twins. 13, 14, 33 Blickstein et al. noted a significantly reduced incidence of RDS or IVH grade III/IV, however, when a complete course of ACS was delivered between 24 hours and 7 days before delivery, compared with partial treatment (delivery <24 hours after the first dose or >7 days after the last dose) or no treatment. 34, 35 Furthermore, some studies found a significant ACS effect in twins only for some outcomes. Vaz et al. 20 highlighted significantly reduced respiratory complications with a complete or rescue ACS course, versus no ACS, but no significant difference for neonatal death or IVH. We observed significantly reduced neurological complications and in-hospital mortality with a complete course of ACS versus no ACS. Yet, as ACS may be less effective in twins than in singletons, it will be interesting to complete this study by comparing neonatal outcomes between twins and singletons to determine whether twin pregnancies may require higher ACS doses.
The ACS-to-delivery interval appears to be fundamental to the benefit of the treatment, but the optimal interval has not yet been clearly established. Various studies investigating the link between this interval and ACS efficacy suggest that ACS is possibly less effective when given more than 7 days before delivery; however, the results were not always consistent with this hypothesis. Peaceman et al. 23 showed an increasing need of short-term respiratory support if the ACS-to-delivery interval exceeded 7 days, but no difference in other morbidity. Likewise, Melamed et al. 19 found an increased risk of composite adverse outcome when ACS was administered more than 7 days before birth, compared with an interval of 1-7 days before birth. Conversely, Sehdev et al. 25 found no differences in neonatal outcomes according to the time interval in 325 singletons. Kuk et al. 26 noted significantly reduced RDS in 468 twins after ACS therapy only if the administration-to-delivery interval was between 2 and 7 days. Similarly, Kosinska-Kaczynska et al. 27 showed that delivery within 7 days after ACS therapy significantly influenced the incidence of RDS in preterm twins. These two studies just analysed RDS, however. We observed less benefit of ACS therapy in twins born at 24-31 weeks of gestation if the ACS-to-delivery interval exceeded 7 days. A single ACS course with an interval of >7 days did not significantly reduce in-hospital mortality. These findings must be interpreted in the context of a large observational study with strong methodology, but collecting a wide range of outcomes. The confidence interval ranges associated with the two comparisons (ACS-to-delivery interval of ≤7 days versus no ACS, and ACS-to-delivery interval of >7 days versus no ACS) and the frequency of the outcomes considered in both groups were rather similar, whereas the odds ratios associated with the effect of an ACS-to-delivery interval of ≤7 days were lower than those associated with the effect of an ACSto-delivery interval of >7 days, especially for mortality. Our evidence, although not conclusive, provides additional support for greater efficacy when corticoid administration is not too distant from delivery.
The reduced effectiveness after 7 days raises the issue of repeating doses when women are still at risk for preterm delivery after 7 days, as well as the question of ACS administration very early in twin pregnancies, particularly when the risk of preterm labour is moderate. The Cochrane Review found a reduction of RDS or serious infant outcomes when doses were repeated after 7 days, compared with no repeated ACS treatment. 12 But repeated doses were also associated with lower mean birthweights. 12, 36, 37 The long-term effects require further research. We found no significant difference in short-term neonatal outcomes when comparing repeated courses with a single course of ACS. Notably, in mothers who received a single complete course, an interval of >7 days was significantly more frequent in twins than in singletons (46.8 versus 35.5, P = 0.0007).
Conclusion
Our results provided additional evidence that the administration of a single complete course of corticosteroids reduced the incidence of severe neurological morbidities and composite outcome in twins born between 24 and 31 completed weeks of gestation, whereas in-hospital mortality was reduced only when the interval between ACS administration and delivery was ≤7 days.
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